Scientists / Our Scientists

Joachim Rudolph

Senior Fellow, Discovery Chemistry, Discovery Oncology, Drug Discovery

Postdoc Mentor

Years at Genentech

Publications at Genentech

Awards & Honors

I joined Genentech in 2007 with 10 years of prior industry experience in the US and Germany.

I did my doctoral studies in organic chemistry at the Max-Planck Institute in Mülheim, Germany, in the group of Manfred Reetz, followed by a post-doctoral stay at The Scripps Research Institute in the laboratory of K. Barry Sharpless. My pharmaceutical industry career began in 1997 at Bayer in Germany and continued in the Bayer Pharmaceutical Research Center in West Haven, Connecticut until 2007.

At Genentech, I have been a chemistry team leader and project leader for multiple small-molecule discovery programs, with a focus in the area of oncology and a growing involvement in early discovery programs and new modalities.

Postdoctoral Mentor

I enjoy working with young scientists with an interest in interdisciplinary research and a drive to venture into the unknown. Genentech offers endless opportunities for collaboration and a fantastic environment to make important discoveries happen.

Featured Publication

Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance

Cancer Discov 2021, 11 (4), 815–821

Rudolph, J.; Settleman, J.; Malek, S.

View Abstract

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor

J Med Chem 2021, 64 (7), 3940–3955.

Huestis, M. P.; Cruz, D. D.; DiPasquale, A. G.; Durk, M. R.; Eigenbrot, C.; Gibbons, P.; Gobbi, A.; Hunsaker, T. L.; La, H.; Leung, D. H.; Liu, W.; Malek, S.; Merchant, M.; Moffat, J. G.; Muli, C. S.; Orr, C. J.; Parr, B. T.; Shanahan, F.; Sneeringer, C. J.; Wang, W.; Yen, I.; Yin, J.; Siu, M.; Rudolph, J.

View Abstract

I lead multiple cross-functional project teams to discover small molecule cancer drugs. I thrive on the day-to-day interactions with chemists, biologists, toxicologists, and other scientists who are all working towards a common goal.

I believe that chemists have unique skill sets and imagination to contribute to the innovation needed to tackle the non-traditional drug target space. I have a particular interest in leveraging new modalities to tackle such targets, and have the firm believe that by bringing the right people and technologies together, any biological target can eventually be drugged.

ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway

Cancer Research Communications,

Jeffrey J. Rodvold; Matt Grimmer; Karen Ruiz; Scot A. Marsters; Ioanna Oikonomidi; Eileen Tan-Aristy; Victoria Pham; Tamal Sarkar; Jonathan M. Harnoss; Whitney Shatz; Zora Modrusan; Thomas D Wu; Jennie R. Lill; Elisia Villemure; Joachim Rudolph; Felipe de Sousa e Melo; Avi Ashkenazi

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Joachim Rudolph

Senior Fellow, Discovery Chemistry, Discovery Oncology, Drug Discovery

Featured Publication

Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor